Marc Albert Bouffard, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Optic Neuritis | 3 | 2023 | 174 | 2.140 |
Why?
|
Optic Nerve Diseases | 4 | 2023 | 342 | 2.120 |
Why?
|
Neuromyelitis Optica | 3 | 2023 | 264 | 1.700 |
Why?
|
Vision, Monocular | 2 | 2023 | 71 | 1.410 |
Why?
|
Oculomotor Nerve Diseases | 2 | 2017 | 54 | 1.090 |
Why?
|
Retinal Artery Occlusion | 2 | 2023 | 77 | 1.050 |
Why?
|
Giant Cell Arteritis | 2 | 2022 | 306 | 1.020 |
Why?
|
Papilledema | 2 | 2023 | 130 | 0.950 |
Why?
|
Vision Disorders | 5 | 2023 | 1088 | 0.880 |
Why?
|
Intracranial Hypertension | 2 | 2022 | 193 | 0.750 |
Why?
|
Eye Diseases | 3 | 2021 | 653 | 0.730 |
Why?
|
Scotoma | 1 | 2021 | 130 | 0.700 |
Why?
|
Hallucinations | 1 | 2022 | 366 | 0.670 |
Why?
|
Diplopia | 2 | 2017 | 214 | 0.650 |
Why?
|
Ventriculoperitoneal Shunt | 1 | 2020 | 187 | 0.630 |
Why?
|
Blindness | 2 | 2023 | 585 | 0.590 |
Why?
|
Isaacs Syndrome | 1 | 2017 | 5 | 0.580 |
Why?
|
Ethambutol | 1 | 2017 | 59 | 0.560 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2017 | 76 | 0.550 |
Why?
|
Carbamazepine | 1 | 2017 | 224 | 0.530 |
Why?
|
Pseudotumor Cerebri | 3 | 2022 | 108 | 0.510 |
Why?
|
Multiple Sclerosis | 2 | 2023 | 3222 | 0.510 |
Why?
|
Visual Fields | 1 | 2021 | 1062 | 0.470 |
Why?
|
Ophthalmology | 2 | 2018 | 550 | 0.470 |
Why?
|
Valproic Acid | 1 | 2017 | 443 | 0.460 |
Why?
|
Oculomotor Muscles | 1 | 2017 | 406 | 0.430 |
Why?
|
Cataract Extraction | 1 | 2017 | 467 | 0.430 |
Why?
|
Neurotoxicity Syndromes | 1 | 2017 | 301 | 0.430 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 915 | 0.410 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2021 | 1073 | 0.390 |
Why?
|
Tomography, Optical Coherence | 3 | 2023 | 2917 | 0.380 |
Why?
|
Susac Syndrome | 2 | 2023 | 22 | 0.370 |
Why?
|
Retinal Ganglion Cells | 1 | 2017 | 810 | 0.360 |
Why?
|
Neurosurgical Procedures | 1 | 2020 | 2067 | 0.320 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4172 | 0.300 |
Why?
|
Optic Nerve | 2 | 2021 | 572 | 0.290 |
Why?
|
Visual Acuity | 1 | 2017 | 2676 | 0.290 |
Why?
|
Anticonvulsants | 1 | 2017 | 1910 | 0.280 |
Why?
|
Diagnosis, Differential | 5 | 2022 | 12966 | 0.240 |
Why?
|
Ultrasonography | 1 | 2017 | 5965 | 0.230 |
Why?
|
Optic Neuropathy, Ischemic | 1 | 2024 | 86 | 0.210 |
Why?
|
Fluorescein Angiography | 3 | 2023 | 1060 | 0.210 |
Why?
|
Dementia | 1 | 2017 | 2686 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 9 | 2023 | 36401 | 0.210 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 153 | 0.210 |
Why?
|
Aquaporin 4 | 1 | 2023 | 161 | 0.210 |
Why?
|
Retina | 3 | 2023 | 2655 | 0.200 |
Why?
|
Methylprednisolone | 1 | 2023 | 385 | 0.200 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6483 | 0.190 |
Why?
|
Supranuclear Palsy, Progressive | 1 | 2021 | 81 | 0.190 |
Why?
|
Pandemics | 1 | 2021 | 8652 | 0.180 |
Why?
|
Myasthenia Gravis | 1 | 2024 | 214 | 0.180 |
Why?
|
Eye Pain | 1 | 2021 | 46 | 0.180 |
Why?
|
Myositis | 1 | 2024 | 269 | 0.180 |
Why?
|
Arnold-Chiari Malformation | 1 | 2022 | 158 | 0.180 |
Why?
|
Blood Cell Count | 1 | 2021 | 397 | 0.170 |
Why?
|
Visual Field Tests | 1 | 2021 | 411 | 0.160 |
Why?
|
Meningitis, Aseptic | 1 | 2018 | 59 | 0.160 |
Why?
|
Sweet Syndrome | 1 | 2018 | 58 | 0.150 |
Why?
|
Humans | 26 | 2024 | 760740 | 0.150 |
Why?
|
Cerebrospinal Fluid | 1 | 2021 | 544 | 0.150 |
Why?
|
Mycobacterium avium Complex | 1 | 2017 | 60 | 0.140 |
Why?
|
Strabismus | 1 | 2021 | 317 | 0.140 |
Why?
|
Korsakoff Syndrome | 1 | 2016 | 18 | 0.140 |
Why?
|
Remission, Spontaneous | 1 | 2017 | 384 | 0.140 |
Why?
|
Optic Disk | 1 | 2021 | 421 | 0.140 |
Why?
|
Retrospective Studies | 8 | 2024 | 80583 | 0.130 |
Why?
|
Retreatment | 1 | 2017 | 596 | 0.120 |
Why?
|
Adenine | 1 | 2021 | 985 | 0.120 |
Why?
|
Postoperative Complications | 1 | 2017 | 15609 | 0.120 |
Why?
|
Adrenal Cortex Hormones | 1 | 2022 | 1878 | 0.110 |
Why?
|
Autoantibodies | 1 | 2021 | 2115 | 0.100 |
Why?
|
Acute Disease | 1 | 2023 | 7236 | 0.100 |
Why?
|
Piperidines | 1 | 2021 | 1655 | 0.100 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3085 | 0.100 |
Why?
|
Aged | 7 | 2024 | 169092 | 0.090 |
Why?
|
Drug Monitoring | 1 | 2017 | 960 | 0.090 |
Why?
|
Female | 10 | 2024 | 392203 | 0.090 |
Why?
|
Magnetic Resonance Angiography | 1 | 2017 | 1431 | 0.090 |
Why?
|
Comorbidity | 2 | 2021 | 10507 | 0.080 |
Why?
|
Antitubercular Agents | 1 | 2017 | 1375 | 0.080 |
Why?
|
Nervous System Diseases | 1 | 2018 | 1662 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 2 | 2021 | 20556 | 0.060 |
Why?
|
Pain | 1 | 2021 | 5062 | 0.060 |
Why?
|
Middle Aged | 7 | 2024 | 220603 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10754 | 0.060 |
Why?
|
Complement Inactivating Agents | 1 | 2024 | 53 | 0.060 |
Why?
|
Tegmentum Mesencephali | 1 | 2021 | 59 | 0.050 |
Why?
|
Encephalocele | 1 | 2022 | 135 | 0.050 |
Why?
|
Brain | 2 | 2018 | 27100 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12143 | 0.040 |
Why?
|
Mesencephalon | 1 | 2021 | 333 | 0.040 |
Why?
|
Prednisone | 1 | 2024 | 1562 | 0.040 |
Why?
|
Male | 7 | 2024 | 360402 | 0.040 |
Why?
|
Young Adult | 3 | 2023 | 59191 | 0.040 |
Why?
|
Nephritis, Interstitial | 1 | 2018 | 155 | 0.040 |
Why?
|
Polycythemia Vera | 1 | 2018 | 161 | 0.040 |
Why?
|
Fundus Oculi | 1 | 2018 | 556 | 0.030 |
Why?
|
Vertigo | 1 | 2018 | 202 | 0.030 |
Why?
|
Adult | 3 | 2023 | 220995 | 0.030 |
Why?
|
Stroke | 1 | 2018 | 9715 | 0.030 |
Why?
|
Atrophy | 1 | 2021 | 1632 | 0.030 |
Why?
|
Tinnitus | 1 | 2018 | 196 | 0.030 |
Why?
|
Uveitis | 1 | 2018 | 396 | 0.030 |
Why?
|
Retinal Diseases | 1 | 2018 | 704 | 0.030 |
Why?
|
Hearing Loss | 1 | 2018 | 781 | 0.020 |
Why?
|
Recurrence | 1 | 2023 | 8426 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2017 | 64572 | 0.020 |
Why?
|
Incidence | 1 | 2024 | 21339 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9277 | 0.020 |
Why?
|
Immunotherapy | 1 | 2018 | 4642 | 0.010 |
Why?
|
Disease Progression | 1 | 2016 | 13495 | 0.010 |
Why?
|
Hypertension | 1 | 2018 | 8532 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2024 | 58919 | 0.010 |
Why?
|
Risk Factors | 1 | 2024 | 74128 | 0.010 |
Why?
|